株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

大腸がん治療法の世界市場:2019年〜2023年

Global Colorectal Cancer Therapeutics Market 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 797420
出版日 ページ情報 英文 128 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.58円で換算しております。
Back to Top
大腸がん治療法の世界市場:2019年〜2023年 Global Colorectal Cancer Therapeutics Market 2019-2023
出版日: 2019年02月22日 ページ情報: 英文 128 Pages
概要

世界の大腸がん治療法市場では、小分子キナーゼ阻害剤の開発が最新トレンドとして活発になっています。また、大腸がんの危険因子を持つ人口の増加が市場成長を推進する主な要因の1つです。しかしながら、市販薬に関連する副作用が市場の成長を妨げる要因となっています。

当レポートでは、世界の大腸がん治療法市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 レポートの範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場エコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年〜2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 市場セグメンテーション:タイプ別

  • 市場セグメンテーション:タイプ別
  • タイプ別比較:市場規模および予測(2018年〜2023年)
  • 標的療法
  • 免疫療法
  • 化学療法
  • 市場機会:タイプ別

第7章 顧客情勢

第8章 地域情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年〜2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第9章 意思決定の枠組み

第10章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第11章 市場動向

第12章 ベンダー情勢

  • 概要
  • 創造的破壊の状況
  • 競合シナリオ

第13章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Sanofi

第14章 付録

  • 調査方法
  • 略語のリスト

第15章 TECHNAVIOについて

図表
  • Exhibit 01: Global oncology therapeutics market
  • Exhibit 02: Segments of global oncology therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Type - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by type
  • Exhibit 19: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Targeted therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Targeted therapies in Phase III for colorectal cancer treatment
  • Exhibit 22: Immunotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Immunotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Chemotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Market opportunity by type
  • Exhibit 27: Customer landscape
  • Exhibit 28: Market share by geography 2018-2023 (%)
  • Exhibit 29: Geographic comparison
  • Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: Colorectal cancer rate based on gender in US 2015
  • Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in North America
  • Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Europe
  • Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in Asia
  • Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 42: Top 3 countries in ROW
  • Exhibit 43: Key leading countries
  • Exhibit 44: Market opportunity
  • Exhibit 45: Rate of colorectal cancer by age in the US
  • Exhibit 46: Global geriatric population
  • Exhibit 47: Combination therapies for colorectal cancer treatment
  • Exhibit 48: Late-stage combination therapies for treatment of colorectal cancer
  • Exhibit 49: Estimated patent expiry dates of a few therapeutics used for colorectal cancer treatment
  • Exhibit 50: Impact of drivers and challenges
  • Exhibit 51: Some of the kinase inhibitors under development for colorectal cancer treatment
  • Exhibit 52: Vendor landscape
  • Exhibit 53: Landscape disruption
  • Exhibit 54: Vendors covered
  • Exhibit 55: Vendor classification
  • Exhibit 56: Market positioning of vendors
  • Exhibit 57: Bristol-Myers Squibb Company - Vendor overview
  • Exhibit 58: Bristol-Myers Squibb Company - Business segments
  • Exhibit 59: Bristol-Myers Squibb Company - Organizational developments
  • Exhibit 60: Bristol-Myers Squibb Company - Geographic focus
  • Exhibit 61: Bristol-Myers Squibb Company - Key offerings
  • Exhibit 62: Bristol-Myers Squibb Company - Key customers
  • Exhibit 63: Eli Lilly and Company - Vendor overview
  • Exhibit 64: Eli Lilly and Company - Business segments
  • Exhibit 65: Eli Lilly and Company - Organizational developments
  • Exhibit 66: Eli Lilly and Company - Geographic focus
  • Exhibit 67: Eli Lilly and Company - Segment focus
  • Exhibit 68: Eli Lilly and Company - Key offerings
  • Exhibit 69: Eli Lilly and Company - Key customers
  • Exhibit 70: F. Hoffmann-La Roche Ltd - Vendor overview
  • Exhibit 71: F. Hoffmann-La Roche Ltd - Business segments
  • Exhibit 72: F. Hoffmann-La Roche Ltd - Organizational developments
  • Exhibit 73: F. Hoffmann-La Roche Ltd - Geographic focus
  • Exhibit 74: F. Hoffmann-La Roche Ltd - Segment focus
  • Exhibit 75: F. Hoffmann-La Roche Ltd - Key offerings
  • Exhibit 76: F. Hoffmann-La Roche Ltd - Key customers
  • Exhibit 77: Merck & Co., Inc. - Vendor overview
  • Exhibit 78: Merck & Co., Inc. - Business segments
  • Exhibit 79: Merck & Co., Inc. - Organizational developments
  • Exhibit 80: Merck & Co., Inc. - Geographic focus
  • Exhibit 81: Merck & Co., Inc. - Segment focus
  • Exhibit 82: Merck & Co., Inc. - Key offerings
  • Exhibit 83: Merck & Co., Inc. - Key customers
  • Exhibit 84: Sanofi - Vendor overview
  • Exhibit 85: Sanofi - Business segments
  • Exhibit 86: Sanofi - Organizational developments
  • Exhibit 87: Sanofi - Geographic focus
  • Exhibit 88: Sanofi - Segment focus
  • Exhibit 89: Sanofi - Key offerings
  • Exhibit 90: Sanofi - Key customers
  • Exhibit 91: Validation techniques employed for market sizing
目次
Product Code: IRTNTR30886

About this market

The global colorectal cancer therapeutics market is largely dominated by monotherapy drugs, including targeted therapies and immunotherapies. However, the combination of these monotherapy drugs with chemotherapy or other therapeutics also increases the therapeutic value. The combination of drugs helps in overcoming the limitations of each therapeutic and increases the overall outcome in the treatment of colorectal cancer. Furthermore, the combination of therapies with or without surgery can be used to reduce the spreading of the disease and temporarily shrink a cancerous tumor. Moreover, the combination therapy that contains two or more number of therapeutics is useful to achieve an additive or synergistic effect with low doses of combinational therapeutics. Technavio's analysts have predicted that the colorectal cancer therapeutics market will register a CAGR of almost 3% by 2023.

Market Overview

Rising population with risk factors of colorectal cancer

The incidence of colorectal cancer is increasing owing to the risk factors such as the increasing geriatric population, inflammatory diseases, genetic syndromes, and changes in lifestyle. Hence, an increase in the number of patients with these risk factors is expected to increase the development of colorectal cancer. This, in turn, is expected to aid in the use of available therapeutics, which will drive the growth of the global colorectal cancer therapeutics market during the forecast period.

Patent expiration of novel therapeutics

The pharmaceutical companies sell their innovator products, especially biologics, at a high price until their patent expiration. The expiration of patents and other intellectual property rights of therapeutics are likely to hamper the growth of the global colorectal cancer therapeutics market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the colorectal cancer therapeutics market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fairly concentrated and with the presence of limited vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1. Preface
  • 2.2. Preface
  • 2.3. Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Targeted therapy - Market size and forecast 2018-2023
  • Immunotherapy - Market size and forecast 2018-2023
  • Chemotherapy - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Sanofi

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations

PART 15: EXPLORE TECHNAVIO

Back to Top